Results

1–7 of 7 results for NDP

Aflibercept 8 mg in Treatment-Naive Macular Edema Secondary to Retinal Vein Occlusion: Primary Endpoint Results From the QUASAR Study
Seenu M. Hariprasad, MD
Annual Meeting Talks
2025
Intravitreal Tarcocimab Tedromer for Diabetic Retinopathy: First-time, Primary Endpoint Results from the Phase 3 GLOW2 Trial
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2026
Use of Ellipsoid Zone Analysis As an Efficacy Endpoint in Clinical Trials for Geographic Atrophy
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2023
Two-Year Real-World Treat and Extend Patterns and Fluid Outcomes Among Neovascular Age-Related Macular Degeneration Patients Treated With Anti-VEGFs
Michael A. Singer, MD
Annual Meeting Talks
2020
X-Files Case, Winter 2020
David Sarraf, MD
2020
APEX: A Phase II Randomized Clinical Trial Evaluating the Safety andPreliminary Efficacy of X-82 Administered Orally in the Treatment of Exudative AMD
Michael N. Cohen, MD
Updates from the Field
2020
Progression of Visual Function Endpoints in Early and Intermediate Age-Related Macular Degeneration
Eleonora Lad, MD, PhD
Annual Meeting Talks
2018